Total human chorionic gonadotropin (hCG-hCG/3) in serum was assayed with the Immulite system, a fully automated random-access immunoassay analyzer that has a unique centrifugal procedure for solid-phase washing and a chemiluminescent detection system. The broad range of the hCG calibration curve (up to 5000 lU/L) is achieved by using a small serum sample size ( hCG is a 237-amino-acid polypeptide of 36 700 Da molecular mass. This glycoprotein is composed of two dissimilar noncovalently bound subunits (2). Synthesis of both subunits appears to be independent; they are further glycosylated and eventually combine with each other or are secreted as separate free a-and free (3-sub- cluding the free /3-chains) minimizes unnecessary chemotherapy in patients entering remission and provides an early indicator for additional chemotherapy if and when hCG becomes detectable. This is most evident in comparisons between assays that measure only the native hCG, the total hCG (hCG + free /3 hCG), the free (3-subunit, and the free a-subunit (6, 7, [11] [12] [13] [14] [15] [16] by a high sensitivity and a broad dynamic working range (hCG calibration curve up to 5000 lU/L), with routine IRMA methodology Besides the analytical evaluation, we compared the hCG-hCG(3 concentrations during normal pregnancy, in follow-up of ectopic pregnancies and molar pregnancies, and in one man with a tumor of the genital tract.
units. The (3-subunit is highly specific for hCG, and antibodies have been developed to give no or minimal cross-reaction with LH, which is especially important for measuring low concentrations of hCG in the diagnosis and management of very early pregnancies, ectopic pregnancies and their follow-ups, threatened abortions, monitoring of neoplasms and trophoblastic diseases, and follow-ups of tumors of the male genital tract (3-10). (11) demonstrated increased serum free (3-subunit concentrations in patients with malignant tumors and suggested that such increases may have important clinical implications. For instance, reliable monitoring of serum total hCG (including the free /3-chains) minimizes unnecessary chemotherapy in patients entering remission and provides an early indicator for additional chemotherapy if and when hCG becomes detectable. This is most evident in comparisons between assays that measure only the native hCG, the total hCG (hCG + free /3 hCG), the free (3-subunit, and the free a-subunit (6, 7, [11] [12] [13] [14] [15] [16] to an unstable anion. The decomposition of the anion yields a sustained emission of light. The photon output is quantified after 10 mm of incubation by a luminometer and is proportional to the hCG concentration in the sample.
Studies of hCG heterogeneity
The Immulite instrument automatically handles the addition of the serum samples and reagents, the incubation under intermittent agitation, the four spin-wash steps, and the measurement by the temperature-controlled luminometer. Test results from the measured signal are calculated by using a stored master curve, and a report with the patient's information (previously stored on a computer) is printed.
The Immulite hCG assay has a working ("reportable") 
Analytical Evaluation
The specificity of the Immulite hCG antibodies was checked by adding to human hCG-free serum glycoprotein hormones such as follitropin (FSH), LH, thyrotropin (TSH), and free /3-subunit of hCG. These antigens were affinity-purified and purchased from Scripps Laboratories (San Diego, CA).
The analytical intraassay precision of the hCG assay on Immulite was determined by assaying five serum samples (covering the whole range of the calibration curve) 20 times each. The interassay precision was established with three commercial control samples (Con4, Con5, and Con6; DPC) assayed in 55 runs with three different kits (lot nos. 8, 11, and 13).
The carryover was checked by running a serum sample of 1505 kIU/L (obtained after serial dilutions), followed by three samples of hCG-free serum. The dilution performance was checked by assaying three serum samples undiluted and diluted in hCG-free sample diluent. The ratios between the observed and the expected values were calculated. The possibifity of a high-dose hook effect was tested by assaying three other serum samples with very high hCG concentrations as undiluted and diluted samples in the Immulite hCG and comparing the results with thoseofa traditional hCG IRMA assay (Serono hCG Maiaclone; Biodata, Rome, Italy).
Clinical Evaluation
Human blood samples collected in our study were 
Results and DiscussIon AnalyticalEvaluation
Calibration curve, sensitivity, and cross-reactivity.
Fig. 1 represents a typical calibration
curve in which the obtained luminescence is plotted against the hCG calibrator concentration. The analytical sensitivity, defined as the concentration corresponding to the mean luminescence of the zero dose plus 2 SD, was 0.5 lU/L.
Specificity. The antibodies used in the Immulite assay
system were highly specific, as shown in Table 1 . Indeed, increasing amounts of FSH, LH, and TSH gave only minimal interferences.
HCG, lU/L except for some sera of postmenopausal women, in whom increased hCG concentrations (up to 12.5 lU/L) were observed (4, 7). Figure 2 shows the median hCG concentrations measured during the first trimester of pregnancy with the Immulite hCG and the IRMA hCG kits. Results of the two assays were superimposable.
The distributions of
the hCG values for each pregnancy week were also identical with both techniques (results not shown). Figure 3 showsresults from two patients with ectopic pregnancies. Three other ectopic pregnancies gave similar data (results not shown). Figure 4 shows the hCG concentrations for three patients with molar pregnancies.
All samples with hCG concentrations 3085 kIUfL were assayed undiluted and in 10-to 20000-fold dilutions on the Immulite instrument. No high-dose hook effect was observed. However, the Serono hCG Maiaclone IRMA kit demonstrated a hook effect up to a 100-fold dilution. When corrected for dilution, superimposable results were obtained for both systems. Figure 5 shows hCG concentrations during a follow-up of a tumor of the male genital tract. Results for both systems were supenmposable.
In this particular case, the free (3-subunit of hCG was measured and remained at very low concentrations.
Our data demonstrate that the free (3- (11) stated that detecting and managing trophoblastic diseases required an hCG assay able to react with cleaved, nicked, or damaged hCG molecules produced in variable amounts in such types of pregnancies or tumors. The present study shows that the Immulite assay is suitable for both intact hCG and for the free /3-subunit, which constitute the most frequently encountered forms of the hormone in those pathological situations. However, further investigation of this assay is needed to evaluate the detection of nicked or damaged hCG.
We conclude that the advantages of the Immulite hCG assay are its wide range of quantifiable concentrations (1-5000 lU/L), the absence of a hook effect up to concentrations of 3000 kJU/L, the very low carryover (<0.0002%), the high specificities of the anti-hCG antibodies, and the full recognition of the free /3-subunit. 
